Spironolactone vs Metformin for PCOS: How to Choose and When to Switch

What Each Drug Actually Does in a Woman With PCOS

Spironolactone and metformin address two different biological problems that often overlap in PCOS. Understanding which problem is driving your symptoms tells you which drug fits better.

PCOS is defined by a combination of androgen excess, ovulatory dysfunction, and polycystic ovarian morphology. Most women have both elevated androgens and some degree of insulin resistance, but the ratio varies. One woman may have severe hirsutism with near-normal fasting insulin; another may have minimal hair growth but a fasting glucose creeping toward prediabetes. The drug that fits your profile is the one that targets your dominant mechanism.

How Spironolactone Works

Spironolactone is a mineralocorticoid antagonist originally developed as a diuretic. At doses of 50 to 200 mg per day used in PCOS, it works through two androgen-related actions: it blocks the androgen receptor so testosterone cannot bind to target tissues like the hair follicle and sebaceous gland, and it mildly reduces adrenal androgen synthesis. The result is slower terminal hair growth, reduced acne severity, and, in some women, a reduction in scalp hair thinning over six to twelve months of consistent use.

How Metformin ER Works

Metformin is a biguanide that reduces hepatic glucose output and improves insulin sensitivity in peripheral tissue. In women with PCOS, lower circulating insulin reduces the stimulus for ovarian theca cells to produce excess testosterone. A 2019 Cochrane systematic review of metformin in PCOS found that metformin improves menstrual frequency and increases the likelihood of ovulation compared with placebo. The extended-release formulation (metformin ER) at 1,500 to 2,000 mg per day produces the same metabolic effect with fewer gastrointestinal side effects than immediate-release tablets.

Head-to-Head Evidence: What the Data Actually Show

No large, adequately powered randomized controlled trial has directly compared spironolactone with metformin as monotherapies in women with PCOS. The honest answer is that most of the comparative picture is built from separate trial programs, not a single head-to-head study. You deserve to know that.

Spironolactone Evidence

A 2015 Cochrane review of anti-androgens for PCOS found that anti-androgen therapy, including spironolactone, produced a statistically significant reduction in Ferriman-Gallwey hirsutism scores compared with placebo. The review noted moderate-quality evidence specifically for spironolactone's effect on facial and body hair. Acne outcomes showed similar directional benefit. Menstrual regularity improved less consistently than with metformin or combined oral contraceptives.

Metformin Evidence

The 2019 Cochrane review covering 41 randomized trials of metformin in PCOS confirmed that metformin increases clinical pregnancy rates (odds ratio 1.94, 95% CI 1.10 to 3.44) compared with placebo alone, and meaningfully improves menstrual regularity. The same review found limited benefit for hirsutism scores. Metformin does reduce free androgen index in some women, but the magnitude is smaller than the direct receptor blockade achieved by spironolactone at therapeutic doses.

What This Means Practically

| Outcome | Spironolactone | Metformin ER | |---|---|---| | Hirsutism (Ferriman-Gallwey score) | Significant reduction | Modest or minimal | | Hormonal acne | Good evidence | Limited evidence | | Menstrual regularity | Modest improvement | Strong improvement | | Ovulation / fertility | Not indicated; contraception required | Improves ovulation rate | | Fasting insulin / HOMA-IR | Minimal direct effect | Meaningful reduction | | Weight | Neutral or mild diuretic weight loss | Modest reduction in some women | | Female pattern hair loss | Some benefit; takes 12+ months | Less studied |

Which Symptoms Point You Toward Spironolactone

Spironolactone is the stronger choice when androgen-driven symptoms are your primary complaint and you are not planning to become pregnant in the near term.

Hirsutism

A Ferriman-Gallwey score above 8 in women of European ancestry (or above 4-6 in East Asian women) is considered clinically significant hirsutism. ACOG guidance on PCOS management supports the use of anti-androgen medications, including spironolactone, for hirsutism when cosmetic measures are insufficient. Improvement takes six months minimum; most women see meaningful change by month nine. Start at 50 mg per day and titrate to 100 mg per day based on tolerability and response.

Hormonal Acne

Androgen receptor blockade at the sebaceous gland level reduces sebum output. In a study published in the Journal of the American Academy of Dermatology, spironolactone at 100 mg daily produced clinically meaningful acne reduction in women who had not responded adequately to topical treatments. Dermatology guidelines now list spironolactone as a first-line systemic option for moderate-to-severe acne in adult women, with or without PCOS.

Female Pattern Hair Loss

PCOS-related androgenic alopecia responds to spironolactone in some women, though the evidence base is thinner than for hirsutism. Doses of 100 to 200 mg per day are typically used. Response is slow and partial, and hair shedding may temporarily worsen in the first eight to twelve weeks before improvement appears.

Which Symptoms Point You Toward Metformin

Metformin is the stronger choice when metabolic dysfunction, irregular cycles, or fertility are your primary concerns.

Irregular Periods and Anovulation

The 2019 Cochrane review found metformin increased the odds of regular menstrual cycles (OR 2.49, 95% CI 1.54 to 4.04) compared with placebo. Women who have not had a period in three or more months, or whose cycle length varies by more than ten days, are good candidates for metformin as a first metabolic intervention. Cycle improvement typically appears within three to six months at 1,500 to 2,000 mg ER per day.

Insulin Resistance and Prediabetes

Women with PCOS have a two- to fourfold higher lifetime risk of type 2 diabetes compared with age-matched women without PCOS, according to data cited in ACOG Practice Bulletin 194. If your fasting glucose is between 100 and 125 mg/dL, or your HbA1c is between 5.7% and 6.4%, metformin addresses the problem that is most likely to cause long-term harm. Spironolactone does not.

Metabolic Syndrome Features

Elevated triglycerides, low HDL, elevated blood pressure, and central adiposity cluster in PCOS. Metformin modestly improves the lipid profile and reduces fasting insulin. Spironolactone lowers blood pressure through its diuretic action, but does not directly improve triglycerides or HDL.

Weight-Related PCOS

Women with a BMI >27 and PCOS are more likely to have dominant insulin resistance. Metformin produces modest weight loss of 1 to 2 kg in this group over six to twelve months, which is enough in some women to restore ovulatory cycles without any additional medication.

Life Stage Guide: Reproductive Years, Perimenopause, and Beyond

Your life stage changes which drug fits, sometimes dramatically.

Reproductive Years (Teens Through Late 30s) Not Trying to Conceive

Spironolactone can be used safely if you are on reliable contraception. Combined oral contraceptives (COCs) are often prescribed alongside spironolactone in this group because they independently lower androgens, protect against unintended pregnancy (which is essential given spironolactone's teratogenic risk), and help regulate cycles. Metformin is added when insulin resistance or metabolic features are present. Many women in this group end up on a COC plus spironolactone, with or without metformin.

Reproductive Years: Trying to Conceive

Stop spironolactone before attempting conception. This is non-negotiable. The drug feminizes male fetuses in animal models, and the FDA has not established a safe gestational exposure level in humans. Switch to metformin as your PCOS pharmacologic anchor. ASRM guidance supports metformin use in women with PCOS who are trying to conceive, particularly to improve ovulation. Metformin is often continued through the first trimester in women who conceived while taking it.

Perimenopause (Typically Ages 40 to 51)

Androgen excess may persist or worsen in perimenopause as estrogen falls but testosterone production continues. Hirsutism and acne that appear or worsen in the mid-40s can represent a shift in the estrogen-to-androgen ratio rather than worsening PCOS per se. Spironolactone remains an option in perimenopausal women who are using contraception (cycle unpredictability in perimenopause does not eliminate the small risk of conception). Metformin continues to have a role if insulin resistance or glucose abnormalities are present, which is increasingly common as estrogen falls and visceral fat redistributes.

Post-Menopause

Spironolactone can be continued in post-menopausal women for persistent hirsutism or androgenic alopecia. The contraception requirement no longer applies. Blood pressure and potassium monitoring remain important, particularly in women on ACE inhibitors or ARBs, or those with kidney disease. Metformin continues to have a role in post-menopausal women with insulin resistance or established type 2 diabetes.

Pregnancy, Lactation, and Contraception: What Every Woman Must Know

Spironolactone in Pregnancy: Contraindicated

Spironolactone is a known teratogen in animal studies. It produces feminization of male fetuses through anti-androgenic effects. The FDA has not assigned a traditional pregnancy category under the newer labeling system, but the prescribing information states that spironolactone should not be used during pregnancy. If there is any chance you could become pregnant, you must use effective contraception. The FDA prescribing information for spironolactone recommends discontinuation if pregnancy occurs or is planned.

Spironolactone and Lactation

Spironolactone passes into breast milk in small amounts. Its active metabolite, canrenone, has been detected in breast milk. The clinical significance is uncertain, but most lactation specialists recommend caution. If you are breastfeeding and need pharmacologic treatment for PCOS-related hyperandrogenism, discuss the individual risk-benefit picture with your prescriber.

Metformin in Pregnancy: Generally Considered Safe, Category B Equivalent

Metformin crosses the placenta, but prospective cohort data and the 2019 Cochrane review have not identified increased rates of congenital malformation with first-trimester exposure. Many reproductive endocrinologists continue metformin through the first trimester in women with PCOS to reduce miscarriage risk, though the evidence for that specific benefit is mixed. Some practitioners continue it throughout pregnancy for women with gestational diabetes or type 2 diabetes. ACOG Practice Bulletin 190 on gestational diabetes notes that metformin is an acceptable oral agent during pregnancy when insulin is not used.

Metformin and Lactation

Metformin transfers into breast milk at low levels. The amount an infant receives is estimated at 0.28% of the maternal dose. Major lactation references, including LactMed, consider this compatible with breastfeeding. The NIH LactMed database lists metformin as acceptable during lactation with no adverse infant effects reported.

Contraception Requirements

If you take spironolactone, you need reliable contraception. Combined oral contraceptives are the usual choice because they independently lower androgens and protect endometrium in women with anovulation. If COCs are contraindicated or unwanted, an IUD plus a progestin-only pill or barrier methods should be discussed with your clinician.

When Clinicians Combine Both Drugs

Using spironolactone and metformin together is common practice in women with PCOS who have both significant hyperandrogenism and insulin resistance. There is no pharmacokinetic interaction between the two drugs that limits co-administration. A practical combination approach:

• Metformin ER 1,000 mg with dinner for four weeks, titrated to 1,500 to 2,000 mg per day
• Spironolactone 50 mg per day, titrated to 100 mg after four to eight weeks if tolerated
• COC added if contraception is needed, if endometrial protection is required, or to amplify androgen suppression

Women on both drugs should have potassium and kidney function checked at baseline and at three months. Spironolactone raises serum potassium; metformin is renally cleared and requires adequate kidney function for safe dosing.

Switching Between Spironolactone and Metformin

Switching From Spironolactone to Metformin (Planning Pregnancy)

This is the most common reason to switch direction. The transition should happen at least one menstrual cycle before you plan to start trying to conceive, to allow spironolactone to clear and to give metformin time to establish ovulatory cycles. Stop spironolactone. Start metformin ER at 500 mg with dinner, increase by 500 mg every one to two weeks to a target of 1,500 to 2,000 mg per day. Expect some return of androgen-driven symptoms (acne, hair) within weeks to months of stopping spironolactone, as androgen receptor blockade is no longer present.

Switching From Metformin to Spironolactone (Contraception Now in Place, Metabolic Goals Met)

Some women stabilize their metabolic markers on metformin but still have significant hirsutism or acne. Adding or transitioning to spironolactone is appropriate once reliable contraception is confirmed. Metformin can be tapered slowly if metabolic markers are normal, or continued alongside spironolactone. There is no requirement to stop metformin before starting spironolactone.

Switching Due to Side Effects

Metformin's most common side effects, specifically nausea, bloating, and diarrhea, often resolve on switching from immediate-release to extended-release formulation or on taking the drug with the largest meal of the day. If GI side effects persist beyond twelve weeks on ER, switching to spironolactone for symptom management may be appropriate while assessing whether the metabolic problem needs a different agent (such as inositol, a GLP-1 receptor agonist, or thiazolidinediones in specific cases). Spironolactone's most common side effects are breast tenderness, urinary frequency, and menstrual irregularity; the last of these often improves after two to three cycles.

Who This Is Right For (and Who Should Avoid Each Drug)

Spironolactone: Right For

• Women with documented hyperandrogenism (elevated free testosterone, elevated DHEAS, or high Ferriman-Gallwey score) on reliable contraception
• Women whose primary complaints are hirsutism, hormonal acne, or androgenic alopecia
• Perimenopausal and post-menopausal women with persistent androgen excess

Spironolactone: Avoid If

• You are pregnant, breastfeeding (caution), or trying to conceive
• You have chronic kidney disease (eGFR <30 mL/min/1.73 m²)
• You are taking high-dose potassium supplements or potassium-sparing diuretics
• You have Addison disease or another condition causing hyperkalemia
• You have a blood pressure consistently below 100/60 mmHg

Metformin: Right For

• Women with insulin resistance, prediabetes, or type 2 diabetes and PCOS
• Women trying to restore ovulatory cycles or preparing for conception
• Adolescents with PCOS and metabolic features (where spironolactone use requires additional discussion)
• Women across all life stages who need cycle regulation without the contraception requirement of spironolactone

Metformin: Avoid If

• eGFR is below 30 mL/min/1.73 m² (absolute contraindication) or below 45 (requires prescriber reassessment)
• You have had or are scheduled for a procedure requiring iodinated contrast dye (hold 48 hours before and after)
• You have active liver disease or excessive alcohol use

Monitoring at Each Stage

| Timepoint | Spironolactone | Metformin ER | |---|---|---| | Baseline | Potassium, creatinine, blood pressure | HbA1c, fasting glucose, LFTs, creatinine | | 3 months | Potassium, blood pressure; assess acne/hair | HbA1c or fasting glucose; assess GI tolerance | | 6 months | Ferriman-Gallwey re-score | Menstrual calendar review; repeat metabolic panel | | 12 months | Continue monitoring; consider dose optimization | Annual HbA1c; reassess if trying to conceive |

A Word on Evidence Gaps for Women With PCOS

Women with PCOS have been repeatedly studied in trials primarily designed to measure fertility or metabolic outcomes. Androgen-specific trials have often used hirsutism scoring as a secondary endpoint rather than a primary one. The 2015 Cochrane anti-androgen review explicitly noted that trial quality was moderate and sample sizes were small. The 2019 metformin Cochrane review found similar limitations. There is no adequately powered, prospective, randomized head-to-head trial comparing spironolactone with metformin as monotherapies in women with PCOS, nor one comparing combination therapy against either drug alone. Recommendations are therefore based on mechanism, individual trial data, and expert consensus, rather than direct comparative evidence. When your clinician tells you that one drug is "better," they mean better for your specific symptom profile given the available data, not better in a head-to-head clinical trial.